Finerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY.

ABSTRACT:

Background

Anemia is common in patients with chronic kidney disease and type 2 diabetes. Finerenone improved heart and kidney outcomes in patients with chronic kidney disease and type 2 diabetes in FIDELITY.

Objectives

This post hoc analysis investigated the efficacy and safety of finerenone vs placebo by baseline anemia status.

Methods

Anemia was defined as serum hemoglobin levels <13 g/dL (male) or <12 g/dL (female) or treatment with an erythropoiesis-stimulating agent at baseline. Outcomes included cardiovascular (CV) and kidney composites, hospitalization for heart failure, and all-cause mortality. Safety was assessed through treatment-emergent adverse events.

Results

Of 12,971 patients, 33% had anemia at baseline. Finerenone reduced the risk of the CV comp

SUBMITTER: Singh AK 

PROVIDER: S-EPMC11905162 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature